ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 400 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.54, for a total value of $23,816.00.
• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total value of $21,568.00.

ANI Pharmaceuticals Stock Up 1.7 %

Shares of ANIP opened at $62.49 on Friday. The business’s 50 day moving average is $58.26 and its 200 day moving average is $58.13. The company has a market capitalization of $1.36 billion, a PE ratio of -113.62 and a beta of 0.62. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Principal Financial Group Inc. raised its stake in ANI Pharmaceuticals by 6.9% during the 3rd quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock valued at $5,367,000 after purchasing an additional 5,829 shares during the period. Victory Capital Management Inc. increased its stake in ANI Pharmaceuticals by 153.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock worth $771,000 after acquiring an additional 7,825 shares during the last quarter. Mizuho Markets Americas LLC bought a new stake in ANI Pharmaceuticals in the 3rd quarter worth approximately $11,670,000. Natixis Advisors LLC increased its stake in ANI Pharmaceuticals by 56.2% in the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock worth $1,085,000 after acquiring an additional 6,545 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 3rd. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $80.00 target price on the stock. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.78.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.